Хайдер Варрайч - Сердце, которое мы не знаем. История важнейших открытий и будущее лечения сердечно-сосудистых заболеваний

Sheldon. F. Mason Sones.

Hurst J. W., King S. B., 3rd, Greene L. In Memory of Andreas Roland Gruentzig and Margaret Anne Thornton Gruentzig. American Journal of Cardiology. 1986;57:333–6.

Там же.

Barton M., Gruntzig J., Husmann M., Rosch J. Balloon Angioplasty – The Legacy of Andreas Gruntzig, M.D. (1939–1985). Frontiers in Cardiovascular Medicine. 2014; 1:15.

Hurst J. W. The First Coronary Angioplasty as Described by Andreas Gruentzig. American Journal of Cardiology. 1986;57:185–6.

Byrne R..A., Capodanno D., Mylotte D., Serruys P. W. State of the Art: 40 Years of Percutaneous Cardiac Intervention. EuroIntervention. 2017;13:621–4.

Gruntzig A. Transluminal Dilatation of Coronary-Artery Stenosis. Lancet. 1978;1:263.

Meier B. The First Patient to Undergo Coronary Angioplasty-23-Year Follow-Up. New England Journal of Medicine. 2001;344:144–5.

International Trade Administration. Department of Commerce. 2016 Top Markets Report: Medical Devices. Overview and Key Findings. www.trade.gov/topmarkets/pdf/Medical_Devices_Executive_Summary.pdf.

Psaty B. M., Boineau R., Kuller L. H., Luepker R. V. The Potential Costs of Upcoding for Heart Failure in the United States. American Journal of Cardiology. 1999;84:108–9, A9.

Coding in the Anti-Fraud Era. Skirt the Upcoding Spotlight. Hospital Peer Review. 1997;22:141–3.

Desai N. R., Bradley S. M., Parzynski C. S., et al. Appropriate Use Criteria for Coronary Revascularization and Trends in Utilization, Patient Selection, and Appropriateness of Percutaneous Coronary Intervention. Journal of the American Medical Association. 2015;314:2045–53.

Gupta A., Yeh R. W., Tamis-Holland J.E., et al. Implications of Public Reporting of Risk-Adjusted Mortality Following Percutaneous Coronary Intervention: Misperceptions and Potential Consequences for High-Risk Patients Including Nonsurgical Patients. JACC Cardiovascular Interventions. 2016;9:2077–85.

Boden W. E., O’Rourke R.A., Teo K. K., et al. Optimal Medical Therapy with or without PCI for Stable Coronary Disease. New England Journal of Medicine. 2007;356:1503–16.

Sedlis S. P., Hartigan P. M., Teo K. K., et al. Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease. New England Journal of Medicine. 2015;373:1937–46.

Al-Lamee, Thompson, Dehbi, et al. Percutaneous Coronary Intervention.

Carrozza J. P., Levin T. Periprocedural Complications of Percutaneous Coronary Intervention. UpToDate. Last updated February 8, 2018.

Fornell D. Tempering the Bioresorbable Stent Euphoria Following FDA Clearance of the Absorb. August 2016. www.dicardiology.com/content/blogs/tempering-bioresorbable-stent-euphoria-following-fda-clearance-absorb.

De Rosa R., Silverio A., Varricchio A., et al. Meta-Analysis Comparing Outcomes After Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents in Patients with Acute Coronary Syndromes. American Journal of Cardiology. 2018;122:61–8.

Lenzer J. When Is a Point of View a Conflict of Interest? British Medical Journal. 2016;355: i6194.

de Alencar Neto J. N. Morphine, Oxygen, Nitrates, and Mortality Reducing Pharmacological Treatment for Acute Coronary Syndrome: An Evidence-Based Review. Cureus. 2018;10: e2114.

Gouda P., Bainey K., Welsh R. The Demise of Morphine Oxygen Nitroglycerin Aspirin (MONA). Canadian Journal of Cardiology. 2016;32:1578 e7.

Hayes S. N., Kim E. S.H., Saw J., et al. Spontaneous Coronary Artery Dissection: Current State of the Science: A Scientific Statement From the American Heart Association. Circulation. 2018;137: e523-e57.

Lerner D. J., Kannel W. B. Patterns of Coronary Heart Disease Morbidity and Mortality in the Sexes: A 26-Year Follow-Up of the Framingham Population. American Heart Journal. 1986;111:383–90.

Mehta L. S., Watson K. E., Barac A., et al. Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. Circulation. 2018;137: e30-e66.

Mosca L., Hammond G., Mochari-Greenberger H., et al. Fifteen-Year Trends in Awareness of Heart Disease in Women: Results of a 2012 American Heart Association National Survey. Circulation. 2013;127:1254–63, e1–29.

Pope J. H., Aufderheide T. P., Ruthazer R., et al. Missed Diagnoses of Acute Cardiac Ischemia in the Emergency Department. New England Journal of Medicine. 2000;342:1163–70.

Bugiardini R., Ricci B., Cenko E., et al. Delayed Care and Mortality Among Women and Men with Myocardial Infarction. Journal of the American Heart Association. 2017;6.

Zwas D. R. Redressing the Red Dress: Rethinking the Campaign. Circulation. 2018;137:763–5.

Kragholm K., Halim S. A., Yang Q., et al. Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years. Circulation: Cardiovascular Quality and Outcomes. 2015;8:357–67.

Rosenman R. H., Brand R. J., Jenkins D., Friedman M., Straus R., Wurm M. Coronary Heart Disease in Western Collaborative Group Study. Final Follow-Up Experience of 8 1/2 Years. Journal of the American Medical Association. 1975;233:872–7.

Keys A., Taylor H. L., Blackburn H., Brozek J., Anderson J. T., Simonson E. Coronary Heart Disease Among Minnesota Business and Professional Men Followed Fifteen Years. Circulation. 1963;28:381–95.

Chapman J. M., Massey F. J., Jr. The Interrelationship of Serum Cholesterol, Hypertension, Body Weight, and Risk of Coronary Disease. Results of the First Ten Years’ Follow-up in the Los Angeles Heart Study. Journal of Chronic Diseases. 1964;17:933–49.

Chen G., Levy D. Contributions of the Framingham Heart Study to the Epidemiology of Coronary Heart Disease. JAMA Cardiology. 2016;1:825–30.

Epstein F. H., Ostrander L. D., Jr., Johnson bc, et al. Epidemiological Studies of Cardiovascular Disease in a Total Community – Tecumseh, Michigan. Annals of Internal Medicine. 1965;62:1170–87.

Merkatz R. B., Temple R., Subel S., Feiden K, Kessler DA. Women in Clinical Trials of New Drugs. A Change in Food and Drug Administration Policy. The Working Group on Women in Clinical Trials. New England Journal of Medicine. 1993;329:292–6.

McCormick K.M., Bunting S. M. Application of Feminist Theory in Nursing Research: The Case of Women and Cardiovascular Disease. Health Care of Women International. 2002;23:820–34.

Albrektsen G., Heuch I., Lochen M. L., et al. Lifelong Gender Gap in Risk of Incident Myocardial Infarction: The Tromso Study. JAMA Internal Medicine. 2016;176:1673–9.